FDA’s continued approval of mRNA shots is infuriating some in MAHAnews2025-07-21T18:29:22+00:00July 21st, 2025|Endpoints News|
#IAS25: HIV activists, scientists press for change, fueled by excitement for new PrEP toolsnews2025-07-18T14:07:06+00:00July 18th, 2025|Endpoints News|
#IAS25: As PEPFAR funding gets congressional support, HIV leaders warn of regression for the fieldnews2025-07-16T09:56:08+00:00July 16th, 2025|Endpoints News|
The Trump administration disbanded a federal newborn screening panel. Advocates now face a harder pathnews2025-07-15T13:30:58+00:00July 15th, 2025|Endpoints News|
US investors divided on China’s biotech risenews2025-07-02T15:00:45+00:00July 2nd, 2025|Endpoints News|
Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trialnews2025-07-01T14:48:52+00:00July 1st, 2025|Endpoints News|
A custom ALS drug could help scale rare disease therapiesnews2025-06-18T15:00:06+00:00June 18th, 2025|Endpoints News|
With HIV prevention under attack, how might Gilead’s new PrEP injection fare?news2025-06-13T14:30:31+00:00June 13th, 2025|Endpoints News|
Reality check: Unpacking the $150B GLP-1 market forecastsnews2025-06-11T14:00:23+00:00June 11th, 2025|Endpoints News|
Rebooting dead human brains, biotech seeks to reinvent drug testing worknews2025-06-10T14:00:49+00:00June 10th, 2025|Endpoints News|
